Search Results

Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant for a project entitled “Development of Cell-penetrant DJ-1 Protein as a Therapeutic Candidate for Treatment of Parkinson’s Disease.” This grant supports the Company’s ongoing cell-penetrant DJ-1 protein replacement therapeutic program.

Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant entitled “Quantification of Cys106 of DJ-1 in Distinct Redox States in Parkinson’s Patients’ iPSC-derived Dopaminergic Neurons, Postmortem Brain Tissue and Plasma as a Potential Biomarker of Parkinson’s Disease”.

Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.